Your browser doesn't support javascript.
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.
de Joode, Karlijn; Dumoulin, Daphne W; Tol, Jolien; Westgeest, Hans M; Beerepoot, Laurens V; van den Berkmortel, Franchette W P J; Mutsaers, Pim G N J; van Diemen, Nico G J; Visser, Otto J; Oomen-de Hoop, Esther; Bloemendal, Haiko J; van Laarhoven, Hanneke W M; Hendriks, Lizza E L; Haanen, John B A G; de Vries, Elisabeth G E; Dingemans, Anne-Marie C; van der Veldt, Astrid A M.
  • de Joode K; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Dumoulin DW; Department of Pulmonary Diseases, Erasmus MC, Rotterdam, the Netherlands.
  • Tol J; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
  • Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands.
  • Beerepoot LV; Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands.
  • van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands.
  • Mutsaers PGNJ; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • van Diemen NGJ; Department of Internal Medicine, Bernhoven, Uden, the Netherlands.
  • Visser OJ; Department of Hematology, Isala Hospital, Zwolle, the Netherlands.
  • Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • van Laarhoven HWM; Department of Medical Oncology, Cancer Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Hendriks LEL; Department of Pulmonary Diseases GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
  • de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Dingemans AC; Department of Pulmonary Diseases, Erasmus MC, Rotterdam, the Netherlands.
  • van der Veldt AAM; Department of Medical Oncology and Department of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: a.vanderveldt@erasmusmc.nl.
Eur J Cancer ; 141: 171-184, 2020 12.
Article in English | MEDLINE | ID: covidwho-915424
ABSTRACT
AIM OF THE STUDY Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19.

METHODS:

This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients' characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible.

RESULTS:

Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years (p < 0.001), male gender (p = 0.035), prior or other malignancy (p = 0.045) and active diagnosis of haematological malignancy (p = 0.046) or lung cancer (p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥65 years).

CONCLUSION:

The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Eur J Cancer Year: 2020 Document Type: Article Affiliation country: J.ejca.2020.09.027

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Eur J Cancer Year: 2020 Document Type: Article Affiliation country: J.ejca.2020.09.027